Cargando…
A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
AIM: To investigate whether 1-step titration of the rivastigmine patch (initiated at 5 cm(2) and titrated to 10 cm(2) after 4 weeks) is well tolerated in Japanese patients with Alzheimer's disease (AD) as compared to 3-step titration (initiated at 2.5 cm(2) and titrated by 2.5 cm(2) every 4 wee...
Autores principales: | Nakamura, Yu, Strohmaier, Christine, Tamura, Kaoru, Kataoka, Naoko, Nakano, Masayuki, Oda, Shoichiro, Nishimura, Kazuma, Homma, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637522/ https://www.ncbi.nlm.nih.gov/pubmed/26557135 http://dx.doi.org/10.1159/000439269 |
Ejemplares similares
-
Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch
por: Molinuevo, José L, et al.
Publicado: (2015) -
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2011) -
Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
por: Ueda, Kengo, et al.
Publicado: (2019) -
An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011) -
A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia
por: Farlow, Martin R., et al.
Publicado: (2013)